The Home of the Life Sciences Industry

Explore Latest News

Lisa Lake/Getty Images

Roivant Dives Deeper into AI with $450 Million Buy of Silicon Therapeutics

The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
Photo courtesy of Sarepta.

FDA Approves Third Sarepta Treatment For Duchenne Muscular Dystrophy

The U.S. FDA approved Sarepta Therapeutics’ Amondys 45 (casimersen) for patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation amenable to exon 45 skipping.

Get personalized job alerts

Create a job alert and receive custom job recommendations straight to your inbox.


Post jobs on BioSpace and start building your talent pipeline today. Click the button to access our easy eCommerce site, which lets you purchase and post jobs in just a few clicks.

Post Jobs Now